ClinicalTrials.gg
RecruitingNCT06747871Updated Jan 9, 2026

Opioids, Low Nicotine Cigarettes, and Chronic Pain

An interventional study of Very Low Nicotine Cigarettes (VLNC) and Normal Nicotine Cigarettes (NNC) in Chronic Pain, Tobacco Use and Opioid Substitution Treatment, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Duke University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Chronic Pain by Duke University — 5 open to participants now, 5 under way, none of them phase 3. Chronic Pain · Duke University.

Planned enrollment
12th of 16
60 · median 99
Started
2025
with 1 other
No phase
14 of 19
5 open now
Registered
16th of 19
by date

Among the 19 studies in Chronic Pain by Duke University, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 16th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

5 of the 19 studies in Chronic Pain by Duke University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Chronic Pain by Duke University, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of switching to very low nicotine content (VLNC) cigarettes versus normal nicotine content (NNC) cigarettes on craving, withdrawal, and pain among individuals with chronic pain who smoke cigarettes daily and are attending office-based buprenorphine treatment (OBBT).

03

Conditions studied

  • Chronic Pain
  • Tobacco Use
  • Opioid Substitution Treatment
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 21+ years who smoke cigarettes daily
  • Chronic non-cancer musculoskeletal pain secondary to structural changes (e.g., low back pain, osteoarthritis)
  • Have received stable office-based buprenorphine treatment for opioid use disorder for at least 30 days
  • Self-report smoking at least 10 cigarettes/day
  • Expired breath carbon monoxide (CO) level >8 ppm
  • Have a smartphone capable of running software for ecological momentary assessment
  • Open to exploring the possibility of quitting smoking

Exclusion criteria

Exclusion Criteria:

  • Pain specifically due to cancer
  • Other significant health problems
  • Major surgery within the past 6 months or planned surgery within the timeframe of the study
  • Current disability litigation
  • Use of electronic cigarettes or other non-cigarette tobacco products > 9 of the past 30 days
  • Current use of nicotine replacement therapy or other cessation treatment
  • Current daily or near-daily cannabis use
  • History of psychotic disorder
  • Acute suicidality or current unstable psychiatric disorder
  • Positive pregnancy test
  • Actively seeking smoking cessation treatment
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Very Low Nicotine Cigarette (VLNC) Group

    Participants in this condition will be provided with VLNCs and asked to switch to smoking only study cigarettes for 4 weeks.

    Behavioral: Very Low Nicotine Cigarettes (VLNC)

  • Active comparator
    Normal Nicotine Cigarette (NNC) Group

    Participants in this condition will be provided with NNCs and asked to switch to smoking only study cigarettes for 4 weeks.

    Behavioral: Normal Nicotine Cigarettes (NNC)

Interventions

  • BehavioralVery Low Nicotine Cigarettes (VLNC)

    Spectrum NRC 102/103 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 0.4 mg/g tobacco.

  • BehavioralNormal Nicotine Cigarettes (NNC)

    Spectrum NRC 600/601 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 15.8 mg/g tobacco.

06

What researchers measure

Primary outcomes

  1. Nicotine Dependence as measured by the Fagerstrom Test of Cigarette Dependence (FTCD)

    The FTCD has a total score of 0 to 10, where a greater score indicates a greater physical dependence on nicotine.

    Time frame: Baseline and weekly during study cigarette use (4 weeks)

  2. Cigarettes per Day

    Average cigarettes smoked per day during the past week will be calculated using timeline follow-back methods

    Time frame: Baseline and weekly during study cigarette use (4 weeks)

  3. Pain as measured by the Brief Pain Inventory (BPI)

    The BPI has an averaged score of 0 to 10, where a greater score indicates greater pain.

    Time frame: Baseline, during abstinence sessions, and at weekly visits during study cigarette use (4 weeks)

  4. Mechanical Hyperalgesia

    Mechanical hyperalgesia is a condition that causes increased sensitivity to mechanical stimuli after an injury to the skin. Discriminability and response bias will be assessed using a computerized pressure algometer.

    Time frame: Weekly visits 1 and 5 during study cigarette use (4 weeks), and during abstinence sessions

  5. Smoking Withdrawal as measured by the Minnesota Withdrawal Scale (MNWS)

    The MNWS has a total score range of 0 to 68, where a higher score indicates greater symptoms of withdrawal.

    Time frame: Baseline, during abstinence sessions, and at weekly visits during study cigarette use (4 weeks)

  6. Cigarette Craving as measured by the Questionnaire of Smoking Urges-Brief (QSU-B)

    The QSU-B has a total score range of 0 to 100, where a higher score indicates greater craving.

    Time frame: Baseline, during abstinence sessions, and at weekly visits during study cigarette use (4 weeks)

  7. Cigarette Purchase Task - demand intensity

    Outcomes for the cigarette purchase task will include demand intensity (i.e., consumption at $0) and Omax (i.e., max expenditure at any price point).

    Time frame: Weekly visits 1 and 5 during study cigarette use (4 weeks), and during abstinence sessions

  8. Cigarette Purchase Task - Omax

    Outcomes for the cigarette purchase task will include demand intensity (i.e., consumption at $0) and Omax (i.e., max expenditure at any price point).

    Time frame: Weekly visits 1 and 5 during study cigarette use (4 weeks), and during abstinence sessions

  9. Pain-Smoking Associations as measured by Ecological Momentary Assessment (EMA)

    EMA (also called experience sampling or daily diary method) involves repeated sampling of people's current experiences (e.g. pain) in real time in their natural environments.

    Time frame: Baseline, weeks 1 and 4 of study cigarette use

  10. Buprenorphine-smoking associations as measured by Ecological Momentary Assessment (EMA) - smoking frequency

    Within-person variability in smoking frequency assessed via EMA before and after buprenorphine administration.

    Time frame: Baseline, weeks 1 and 4 of study cigarette use

  11. Buprenorphine-smoking associations as measured by Ecological Momentary Assessment (EMA) - craving

    Within-person variability in smoking craving assessed via EMA before and after buprenorphine administration.

    Time frame: Baseline, weeks 1 and 4 of study cigarette use

  12. Opioid Withdrawal as measured by the Short Opioid Withdrawal Scale (SOWS)

    The SOWS consists of 16 symptoms rated in intensity by patients on a 5-point scale of intensity as follows: 0-not at all, 1-a little, 2-moderately, 3-quite a bit, 4-extremely. The total score ranges from 0 to 64, where a higher score indicates greater symptoms of withdrawal.

    Time frame: Baseline, during abstinence sessions, and at weekly visits during study cigarette use (4 weeks)

Secondary outcomes

  1. Number of participants willing to Quit Smoking

    Decision (yes/no) to engage in the optional quit attempt

    Time frame: post-intervention, after 24 hrs abstinence

  2. Smoking abstinence self-efficacy as measured by the Self-Efficacy Questionnaire (SEQ)

    The SEQ has a total score range of 10 to 40, where a higher score indicates greater self-efficacy.

    Time frame: Weekly visits 1 and 5

  3. Pain and Smoking Inventory (PSI)

    The PSI total score is computed by averaging scores across the nine items. Items are endorsed on a seven-point Likert scale anchored at 0 (not true at all), 3 (somewhat true), and 6 (extremely true). Scores range from 0 to 6, where higher scores indicate greater perceptions that pain and smoking are interrelated.

    Time frame: Weekly visits 1 and 5

  4. Barriers to Quitting Smoking in Substance Abuse Treatment (BSQ-SAT)

    The BQS-SAT is an 11-item true-false instrument of perceived barriers to quitting smoking plus one open-ended item. The score can range from 0 to 4.86, where a higher score indicates a greater perceived barrier.

    Time frame: Weekly visits 1 and 5

07

Study locations

1 of 1 sites recruiting
  • North Pavilion
    Durham, North Carolina 27705, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The final dataset will include demographic, interview and self-report data. The investigators will share de-identified individual-participant level (IPD) data. Appropriate measures will be used for data de-identification and sharing, and informed consent will reflect those plans.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jul 2027, 27 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 27 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 24, 2024
StartActual
Apr 15, 2025
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06747871
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Apr 15, 2025
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Jan 9, 2026

Study contacts

Clinical Research Coordinator
Contact
ta141@duke.edu
919-907-9955
Clinical Research Coordinator
Contact
lgf12@duke.edu
984-327-6157
Maggie Sweitzer, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion